• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Estropipate

CAS No. 7280-37-7

Estropipate ( Piperazine Estrone Sulfate )

产品货号. M15786 CAS No. 7280-37-7

Estropipate is a form of estrogen.

纯度: >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
10MG ¥332 有现货
25MG ¥494 有现货
50MG ¥689 有现货
100MG ¥1021 有现货
200MG ¥1320 有现货
500MG ¥2989 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    Estropipate
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Estropipate is a form of estrogen.
  • 产品描述
    Estropipate is a form of estrogen. It has several uses such as: Alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics,treatment of vaginal atrophy,treatment of some types of breast Y (particularly in men and postmenopausal women), treatment of prostate Y and prevention of osteoporosis.
  • 同义词
    Piperazine Estrone Sulfate
  • 通路
    Endocrinology/Hormones
  • 靶点
    Estrogen Receptor/ERR
  • 受体
    ER
  • 研究领域
    Endocrinology
  • 适应症
    ——

化学信息

  • CAS Number
    7280-37-7
  • 分子量
    436.56
  • 分子式
    C22H32N2O5S
  • 纯度
    >98%(HPLC)
  • 溶解度
    DMSO: 35mg/mL
  • SMILES
    C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O
  • 化学全称
    [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate;piperazine

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Brama M, et al. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):102-8.
产品手册
关联产品
  • Elacestrant dihydroc...

    Elacestrant (RAD-1901) is a novel, orally bioavailable small-molecule selective estrogen receptor degrader (SERD).

  • Prochloraz

    Prochloraz is a broad-spectrum contact imidazole fungicide. Prochloraz inhibits human placental microsomal aromatase in vitro (IC50 = 40 nM).

  • glutamic acid

    (S)-Glutamic acid acts as an excitatory transmitter, shows a direct activating effect on the release of DA from dopaminergic terminals.